** Shares in Novo Nordisk rise around 2% after its controlling shareholder said on Saturday it had fulfilled regulatory conditions to acquire Catalent in the U.S.
** The deal involves the sale of three Catalent manufacturing sites to Novo Nordisk
** The conversion of the Catalent sites will provide Novo with much more filling capacity than is currently anticipated, J.P.Morgan analysts say
** This will allow Novo to not only ramp the U.S. supply of Wegovy faster from 2026, but also the global supply of Ozempic and the supply of Wegovy excluding the U.S. also from 2026, the broker adds
** Separately, Novo Nordisk said it plans to invest 8.5 billion Danish crowns ($1.20 billion) in a new plant in Denmark
** Novo Nordisk shares top the Copenhagen blue chip index
($1 = 7.0971 Danish crowns)
(Reporting by Boleslaw Lasocki)
((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。